Christopher Mintz-Plasse Net Worth and Income Sources
Christopher Mintz-Plasse is an American actor and content creator known for roles in Superbad, Kick-Ass, and Fright Night. His net worth is estimated in the low millions, driven by film salaries, streaming residuals, and digital content revenue. He has expanded income through brand partnerships and social media monetization, as noted on his verified profiles and entertainment databases Forbes.
His primary earnings come from film and television work, with notable appearances in major studio releases and independent projects. He has also generated revenue from YouTube channels and online series, where audience engagement translates into ad income and sponsorships. These diversified income streams reflect a modern entertainment career built on both traditional and digital platforms.
Major Film Roles and Career Highlights
Christopher Mintz-Plasse gained recognition for his role as Fogell in Superbad, a performance that became a cultural touchstone in teen comedy. He later played Chris D'Amico in Kick-Ass, a role that showcased his range in action and dark comedy genres.
Selected Filmography and Box Office Impact
His filmography includes roles in Fright Night, Role Models, and The Lego Movie franchise, where he contributed voice work to a globally successful animated series. These projects have collectively grossed billions worldwide, reinforcing his presence in high-profile productions Box Office Mojo.
Business Ventures and Digital Presence
Christopher Mintz-Plasse has leveraged his entertainment career into business ventures, including content creation and brand collaborations. He maintains active social media accounts where he engages with fans and promotes projects, aligning with current digital marketing trends.
His digital strategy includes long-form content, short-form clips, and interactive campaigns that drive audience growth. These efforts have positioned him as a multifaceted figure in the entertainment industry, blending acting with entrepreneurial content development SEC.